Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Stifel CNS Day Transcript

Mar 31, 2021 / 12:00PM GMT
Release Date Price: €64.06 (+3.82%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Good morning, everybody, and thanks for joining our Third Annual Neuroscience Conference. Definitely great to be starting it off with Barry. It's the first discussion. I think we're doing on camera since you joined Sage, maybe we did one at a conference in the fall, but more -- so no online questions today on Sage. But thank you, man. And maybe you want to kick it off and just sort of set the stage with the update in zuranolone trials, tremor and NMDA, and then we can get into specifics, Barry. That sounds good?

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes. Yes. Thanks, Paul. And I appreciate Stifel for having us. And it's wonderful to kick off your third annual and be the lead company. So yes, things are going incredibly well. I'm excited by the progress we're making at Sage. As I've said before, we're positioned to be a top-tier biopharmaceutical company and the leader in brain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot